logo-loader
viewThe Coca-Cola Company

Coca-Cola sees coronavirus impact in Q1; boosts dividend to $0.41 per share

China, where the virus originated in the city of Wuhan, is Coca-Cola’s third-largest market

The Coca-Cola Company -
Coca-Cola has reaffirmed its full-year guidance and is ratcheting up its dividend by 2.5% to $0.41 per share

The Coca-Cola Company (NYSE:KO) is joining a lengthy list of public companies taking a hit from China’s deadly coronavirus as it expects the outbreak of this epidemic to weigh down its results in the first quarter. 

China, where the virus originated in the city of Wuhan, is Coca-Cola’s third-largest market. And due to its rapid spread, the cola maker now estimates an approximate 2 to 3 point impact to unit case volume; a 1 to 2 point impact to organic revenue; and a 1 to 2 penny impact to earnings per share for the first quarter.

“The situation with COVID-19 – or coronavirus – continues to evolve, and the company expects to provide more information during its next earnings call in April,” the Atlanta, Georgia-based company said in a statement.

Pledges to keep up with investment plans in China

Undeterred by the gravity of the situation, Coca-Cola is pledging to keep up with its plans to invest in China, a key market, for the long-term.

Since it was first reported in late December in Wuhan, the virus has made its way from China to as many as 30 countries; more than 75,000 people have been infected and over 2,000 of those infected have died.

In other news, Coca-Cola has reaffirmed its full-year guidance and is ratcheting up its dividend by 2.5% to $0.41 per share, which will be paid on April 1 to select shareholders.

Quick facts: The Coca-Cola Company

Price: 42.81 USD

NYSE:KO
Market: NYSE
Market Cap: $183.8 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn's therapy used to treat New York coronavirus...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area. Pourhassan, together diagnostics...

1 day, 22 hours ago

2 min read